{
    "clinical_study": {
        "@rank": "52009", 
        "acronym": "EACA", 
        "arm_group": [
            {
                "arm_group_label": "epsilon-aminocaproic acid (EACA)", 
                "arm_group_type": "Active Comparator", 
                "description": "75mg/kg loading dose with infusion 15mg/kg/hr"
            }, 
            {
                "arm_group_label": "EACA", 
                "arm_group_type": "Experimental", 
                "description": "125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery."
            }
        ], 
        "brief_summary": {
            "textblock": "This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and\n      blood transfusion after cardiac surgery without increasing adverse events"
        }, 
        "brief_title": "Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Disease", 
        "condition_browse": {
            "mesh_term": "Aortic Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to sign informed consent\n\n          -  Elective cardiac surgery patients undergoing primary surgery involving circulatory\n             arrest\n\n        Exclusion Criteria:\n\n          -  Inability to sign informed consent\n\n          -  Baseline hypercoagulable condition as defined in medical record\n\n          -  Coronary disease with untreated lesions or recent coronary stent placement\n\n          -  Severe renal dysfunction (ESRD) as documented in medical record"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965730", 
            "org_study_id": "816724"
        }, 
        "intervention": {
            "arm_group_label": [
                "epsilon-aminocaproic acid (EACA)", 
                "EACA"
            ], 
            "intervention_name": "epsilon-aminocaproic acid (EACA)", 
            "intervention_type": "Drug", 
            "other_name": "Amicar"
        }, 
        "intervention_browse": {
            "mesh_term": "6-Aminocaproic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "dilated ascending aorta", 
        "lastchanged_date": "October 17, 2013", 
        "location": {
            "contact": {
                "email": "mary.hammond@uphs.upenn.edu", 
                "last_name": "Mary S Hammond, BSN"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Prakash A Patel, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography", 
        "overall_contact": {
            "email": "mary.hammond@uphs.upenn.edu", 
            "last_name": "Mary S Hammond, BSN", 
            "phone": "2156623772"
        }, 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Prakash A Patel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study will be to determine if a change in EACA dosing for cardiac surgery cases involving circulatory arrest actually leads to a quantifiable change in the degree of fibrinolysis as measured by TEG.", 
            "measure": "degree of fibrinolysis as measured by thromboelastography", 
            "safety_issue": "No", 
            "time_frame": "Length of cardiac surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965730"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}